ReviewPressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications
Introduction
Peritoneal metastasis is a heterogeneous group of primary disease or metastatic spread within the abdominal cavity. The most frequent conditions concern patients with ovarian (up to 46% at initial presentation), gastric (14%), and colorectal (5%) primary tumours, and patients with peritoneal mesothelioma.1, 2, 3, 4 A common feature of peritoneal metastasis is a reduced response to systemic chemotherapy and poor prognosis compared with other metastatic sites, at least in the recurrent setting.5, 6, 7
Intraperitoneal chemotherapy has been proposed as an alternative approach for these patients to improve tissue concentrations and to reduce systemic toxicity.8, 9, 10 This approach is a valid option in several types of malignancies in the adjuvant setting, such as ovarian and gastric cancer, for which phase 3 trials have been done.8, 11, 12 Long-term survival has been reported for different disease entities when combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).13, 14, 15, 16, 17 However, high morbidity and mortality and the unclear role of HIPEC have led to reduced acceptance of this technique within the medical community, despite growing but still controversial high-level evidence.18, 19, 20
Pressurised intraperitoneal aerosol chemotherapy (PIPAC) has been proposed as an alternative mode for intraperitoneal drug delivery in certain situations, claiming improved distribution, enhanced tissue uptake, better tolerance, and repeatability using minimally invasive access.21, 22 The intriguing concept and favourable initial reports23, 24 have triggered the adoption of PIPAC as a drug delivery technique, mainly within Europe (appendix p 1).
We did a systematic review with the aim of detailing the rationale and technique of PIPAC and critically assessing the available evidence of its feasibility, safety, and tolerance and its use in potential indications other than ovarian and gastric cancer.
Section snippets
Literature search strategy and selection criteria
Medical subject heading (MeSH) terms “intraperitoneal” AND “chemotherapy” AND “pressurised” were used to search MEDLINE, Embase, the Cochrane Database of Systematic Review, and the Cochrane Central Register of Controlled Trials without language restrictions. Pertinent references and electronic links were hand-searched, and cross-referencing was done for selected articles. The search was limited to studies published between Jan 1, 2011 (the year PIPAC was first used in humans) and Jan 31, 2019.
Findings
Our systematic literature review identified 106 publications on PIPAC, with a substantial increase in the number of articles published since 2016 (appendix p 2). Excluding 25 preclinical studies, 24 reviews or narrative reports, 10 trial proposals, 2 unpublished conference reports, only 45 clinical studies, including case studies and occupational health studies, were identified (figure 1). Considering overlapping patient cohorts, our analysis included 1810 PIPAC procedures in 838 patients. The
Discussion
PIPAC is a new treatment alternative for patients with peritoneal metastasis and has undergone initial evaluation. Based on 1810 procedures in 838 patients, PIPAC can be considered a feasible, safe, and well tolerated treatment with no negative effect on quality of life. Oncological efficacy has been documented, according to different assessment tools, in 50–88% of patients with advanced peritoneal metastasis who are refractory to standard treatment. The prospective PIPAC registry (NCT03210298)
Conclusion
In summary, PIPAC can be considered a safe and promising treatment alternative for patients with advanced isolated refractory peritoneal disease. Other indications are being studied according to the IDEAL framework, such as prophylactic, neoadjuvant, or adjuvant treatment strategies including treatment combinations with systemic regimens. Reliable results should be available within the next 5–10 years.
References (91)
- et al.
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
Lancet Oncol
(2016) Intraperitoneal antineoplastic drug delivery: rationale and results
Lancet Oncol
(2003)- et al.
Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia
Lancet Oncol
(2004) - et al.
Neoadjuvant treatment of gastric cancer with peritoneal dissemination
Eur J Surg Oncol
(2006) - et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eur J Cancer
(2009) - et al.
Type-specific response to neoadjuvant chemotherapy: ovarian high-grade serous carcinoma versus colorectal mucinous carcinoma
J Obstet Gynaecol Canada
(2012) - et al.
Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study
Eur J Surg Oncol
(2018) - et al.
Pressurized intraperitoneal aerosol chemotherapy—practical aspects
Eur J Surg Oncol
(2017) - et al.
How to perform safe and technically optimized pressurized intraperitoneal aerosol chemotherapy (PIPAC): experience after a consecutive series of 1200 procedures
J Gastrointest Surg
(2018) - et al.
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedure for non-resectable peritoneal carcinomatosis (with video)
J Gastrointest Surg
(2018)
Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis
Eur J Surg Oncol
A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis
Gynecol Oncol
Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study
Gynecol Oncol
Activity of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience
Gynecol Oncol
pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis
J Gastrointest Surg
Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Eur J Surg Oncol
Occupational exposure to platinum drugs during intraperitoneal chemotherapy. Biomonitoring and surface contamination
Toxicol Lett
Occupational exposure to cisplatin/oxaliplatin during pressurized intraperitoneal aerosol chemotherapy (PIPAC)?
Eur J Surg Oncol
No surgical innovation without evaluation: the IDEAL recommendations
Lancet
Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study
Int J Cancer
Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors
Int J Cancer
Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force
JAMA
Advances in the management of peritoneal mesothelioma
World J Gastroenterol
Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure
J Natl Cancer Inst
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
N Engl J Med
Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin
Br J Surg
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
J Clin Oncol
Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study
J Clin Oncol
Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients
Cancer
Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility?
Ann Surg Oncol
Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program
JAMA Surg
Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
Int J Hyperthermia
Hyperthermic intraperitoneal chemotherapy in ovarian cancer
N Engl J Med
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer
J Clin Oncol
Cytoreductive Surgery with and without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Metastasis (CYTO-CHIP study): a propensity-score analysis
J Clin Oncol
Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects
Ann Surg Oncol
Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy
Ann Surg Oncol
Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis
Br J Surg
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
BMJ
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer
Arch Gynecol Obstet
Common terminology criteria for adverse events (CTCAE), version 4.0
Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS)
Pleura Peritoneum
Pathological features of rectal cancer after preoperative radiochemotherapy
Int J Colorectal Dis
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis
[PIPAC—pressurized intraperitoneal aerosol chemotherapy. A novel treatment for peritoneal carcinomatosis]
Rev Med Suisse
Cited by (209)
Insights into synchronous peritoneal metastases from hepatobiliary origin: Incidence, risk factors, treatment, and survival from a nationwide database
2023, European Journal of Surgical OncologyThe Future of Interventions for Stage IV Colorectal Cancers
2024, Clinics in Colon and Rectal SurgeryRegional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease
2024, Journal of Gastrointestinal Cancer
- †
These authors contributed equally